Investigation Alert: Long-Term Investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) should contact the Shareholders Foundation

An investigation on behalf of current long-term investors in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) concerning potential breaches of fiduciary duties by certain directors and officers of Ultragenyx Pharmaceutical Inc. was announced.

Investors who are current long term investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: RARE stocks follows a lawsuit filed against Ultragenyx Pharmaceutical Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in (ASDAQ: RARE stocks, concerns whether certain Ultragenyx Pharmaceutical Inc. directors are liable in connection with the allegations made in that lawsuit.

Novato, CA based Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported that its annual Total Revenue rose from $434.24 million in 2023 to $560.23 million in 2024, and that Net Loss declined from $606.63 million in 2023 to $569.18 million in 2024.

On July 9, 2025, Ultragenyx Pharmaceutical Inc revealed that the Phase III Orbit study failed to achieve statistical significance for the second interim analysis and that Phase III Orbit and Cosmic studies would now be "progressing toward final analysis."

Then, on December 29, 2025, Ultragenyx Pharmaceutical Inc announced that both its Phase III Orbit and Cosmic Studies had not "achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively." The Company attributed the study failure to a "low fracture rate in the placebo group" of Orbit and a trend that fell shy of statistical significance in Cosmic.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) declined from $60.37 per share on September 16, 2024, to as low as $18.41 per share on December 29, 2025.

According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that defendants created the false impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public, and that in truth, Ultragenyx' optimism in the Phase III Orbit study's results and interim analysis benchmark were misplaced because Ultragenyx failed to convey the risk associated with basing such threshold figures on Phase II results that had no placebo control group for appropriate comparison and thus had not ruled out that the reduction in AFR from that study could merely be triggered by an increased standard of care and the placebo effect of being provided a novel treatment.

Those who purchased shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.